PL2203170T3 - Nowe zastosowania terapeutyczne adrenergicznej alfuzosyny - Google Patents

Nowe zastosowania terapeutyczne adrenergicznej alfuzosyny

Info

Publication number: PL2203170T3
Authority: PL; Poland
Prior art keywords: alfuzosine; adrenergic; therapeutic uses; novel therapeutic; novel
Prior art date: 2007-09-26

Application number

PL08833688T

Other languages

English (en)

Inventor

Pierangelo Geppetti

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-26

Filing date

2008-09-24

Publication date

2012-02-29

2008-09-24 Application filed by Sanofi Sa filed Critical Sanofi Sa

2012-02-29 Publication of PL2203170T3 publication Critical patent/PL2203170T3/pl

Links

230000001800 adrenalinergic effect Effects 0.000 title 1
WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL08833688T 2007-09-26 2008-09-24 Nowe zastosowania terapeutyczne adrenergicznej alfuzosyny PL2203170T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US97532407P	2007-09-26	2007-09-26
EP07291148A EP2042179A1 (en)	2007-09-26	2007-09-26	Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
EP08833688A EP2203170B1 (en)	2007-09-26	2008-09-24	NOVEL THERAPEUTIC USES OF ADRENERGIC ALFUZOsINE
PCT/IB2008/003126 WO2009040671A1 (en)	2007-09-26	2008-09-24	Novel therapeutic uses of adrenergic alpha-1 receptor antagonists

Publications (1)

Publication Number	Publication Date
PL2203170T3 true PL2203170T3 (pl)	2012-02-29

Family

ID=38754714

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08833688T PL2203170T3 (pl)	2007-09-26	2008-09-24	Nowe zastosowania terapeutyczne adrenergicznej alfuzosyny

Country Status (15)

Country	Link
US (1)	US8492396B2 (pl)
EP (2)	EP2042179A1 (pl)
JP (1)	JP5478495B2 (pl)
AR (1)	AR068825A1 (pl)
AT (1)	ATE524185T1 (pl)
CY (1)	CY1112203T1 (pl)
DK (1)	DK2203170T3 (pl)
ES (1)	ES2373354T3 (pl)
HR (1)	HRP20110919T1 (pl)
ME (1)	ME01259B (pl)
PL (1)	PL2203170T3 (pl)
PT (1)	PT2203170E (pl)
RS (1)	RS52069B (pl)
SI (1)	SI2203170T1 (pl)
WO (1)	WO2009040671A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20200022908A1 (en) *	2018-07-18	2020-01-23	Wenzhou Medical University	Method for treating myopia and application in preparation of medicament

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2582513B1 (fr) *	1985-05-28	1988-08-05	Synthelabo	Compositions pharmaceutiques contenant de l'alfuzosine
US20020143007A1 (en) *	1996-02-02	2002-10-03	Garvey David S.	Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
HUP0004089A2 (hu) *	1997-07-10	2001-04-28	Therakos, Inc.	A bél és a húgyhólyag gyulladásos rendellenességeinek kezelése testen kívüli fotoferezissel
IL156585A0 (en) *	2001-01-26	2004-01-04	Schering Corp	Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
EP1364659B1 (en) *	2001-02-08	2009-11-11	Ono Pharmaceutical Co., Ltd.	Remedies for urinary diseases comprising lpa receptor controlling agents
IL157734A0 (en) *	2001-03-06	2004-03-28	Cellegy Pharma Inc	Pharmaceutical compositions for the treatment of urogenital disorders
US20030060513A1 (en) *	2001-09-27	2003-03-27	Arneric Stephen P.	Pharmaceutical composition
EP1551394A1 (en) *	2002-08-14	2005-07-13	Janssen Pharmaceutica N.V.	Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
WO2005005395A2 (en) *	2003-07-02	2005-01-20	F. Hoffmann-La Roche Ag	Arylamine-substituted quinazolinone compounds
WO2007047282A1 (en) *	2005-10-12	2007-04-26	Lilly Icos Llc	Treatment of benign prostatic hypertrophy and lower urinary tract symptoms

2007
- 2007-09-26 EP EP07291148A patent/EP2042179A1/en not_active Withdrawn
2008
- 2008-09-24 PL PL08833688T patent/PL2203170T3/pl unknown
- 2008-09-24 DK DK08833688.8T patent/DK2203170T3/da active
- 2008-09-24 ME MEP-2011-204A patent/ME01259B/me unknown
- 2008-09-24 AT AT08833688T patent/ATE524185T1/de active
- 2008-09-24 RS RS20110553A patent/RS52069B/sr unknown
- 2008-09-24 ES ES08833688T patent/ES2373354T3/es active Active
- 2008-09-24 JP JP2010526392A patent/JP5478495B2/ja not_active Expired - Fee Related
- 2008-09-24 SI SI200830471T patent/SI2203170T1/sl unknown
- 2008-09-24 WO PCT/IB2008/003126 patent/WO2009040671A1/en not_active Ceased
- 2008-09-24 HR HR20110919T patent/HRP20110919T1/hr unknown
- 2008-09-24 AR ARP080104131A patent/AR068825A1/es unknown
- 2008-09-24 PT PT08833688T patent/PT2203170E/pt unknown
- 2008-09-24 EP EP08833688A patent/EP2203170B1/en active Active
2010
- 2010-03-24 US US12/730,559 patent/US8492396B2/en not_active Expired - Fee Related
2011
- 2011-12-14 CY CY20111101243T patent/CY1112203T1/el unknown

Also Published As

Publication number	Publication date
ES2373354T3 (es)	2012-02-02
ME01259B (me)	2013-06-20
JP2010540511A (ja)	2010-12-24
DK2203170T3 (da)	2012-01-16
WO2009040671A1 (en)	2009-04-02
EP2203170A1 (en)	2010-07-07
US8492396B2 (en)	2013-07-23
ATE524185T1 (de)	2011-09-15
EP2042179A1 (en)	2009-04-01
WO2009040671A4 (en)	2009-05-28
CY1112203T1 (el)	2015-12-09
AR068825A1 (es)	2009-12-09
HRP20110919T1 (hr)	2012-01-31
JP5478495B2 (ja)	2014-04-23
SI2203170T1 (sl)	2012-01-31
US20110009436A1 (en)	2011-01-13
RS52069B (sr)	2012-06-30
EP2203170B1 (en)	2011-09-14
PT2203170E (pt)	2011-12-27

Publication	Publication Date	Title
PL2954932T3 (pl)	2019-04-30	Zastosowanie terapeutyczne diaminofenotiazyn
GB0716532D0 (en)	2007-10-03	Therapeutic compounds
GB0813087D0 (en)	2008-08-27	Therapeutic compounds
ZA200906187B (en)	2013-02-27	Reducing side effects of tramadol
ZA201003941B (en)	2011-06-29	Use of rr/sr-ractopamine
PL2133419T3 (pl)	2019-02-28	Zastosowania beta-dipeptydów cyjanoficyny
EP2212251A4 (en)	2011-11-02	PROCESS FOR THE PRODUCTION OF CLUSTERBOR
GB0724340D0 (en)	2008-01-30	Novel Therapeutic Agents
IL208236A0 (en)	2010-12-30	Use of cathepsin c
ZA201000225B (en)	2011-03-30	Treatment of depression
ZA200905468B (en)	2010-05-26	Therapeutical uses of eslicarbazepine
IL199765A0 (en)	2010-04-15	Use of tocopherol
GB0723100D0 (en)	2008-01-02	Treatment of HFnEF
EP2205525A4 (en)	2011-06-08	PROCESS FOR THE PREPARATION OF CLUSTERBORON
EP2205524A4 (en)	2011-06-08	METHODS OF MANUFACTURING CLUSTER BORON
GB201114396D0 (en)	2011-10-05	Location of basesation
GB0702862D0 (en)	2007-03-28	Therapeutic compounds
SI2203170T1 (sl)	2012-01-31	Nove terapevtske uporabe adrenergičnega alfuzosina
GB0708188D0 (en)	2007-06-06	Therapeutic compounds
GB0708186D0 (en)	2007-06-06	Therapeutic compounds
GB0705204D0 (en)	2007-04-25	Uses of (S)-clenbuterol
PL383760A1 (pl)	2009-05-25	Nowe zastosowanie undekan-2-olu
PL383759A1 (pl)	2009-05-25	Nowe zastosowanie undekan-2-olu
PL383758A1 (pl)	2009-05-25	Nowe zastosowanie undekan-2-onu
ZA200904356B (en)	2010-08-25	Use of tocopherol